MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, GRI had $3,201K increase in cash & cash equivalents over the period. -$10,189K in free cash flow.

Cash Flow Overview

Change in Cash
$3,201K
Free Cash flow
-$10,189K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Net loss
-11,956
Depreciation expense
4
Stock-based compensation expense
793
Change in fair value of warrant liability
0
Change in operating lease right of use assets
48
Prepaid expenses and other current assets
-251
Accounts payable
663
Accrued expenses
59
Operating lease liabilities
-48
Cash used in operating activities
-10,186
Purchase of property and equipment
3
Cash used in investing activities
-3
Proceeds from issuance of common stock in financing transaction / under atm facility-Through Financing
13,000
Proceeds from issuance of common stock in financing transaction / under atm facility-At The Market Offering
2,560
Proceeds from warrant exercise
0
Payment for fractional shares in connection with reverse stock split
1
Payment of deferred stock issuance costs
2,169
Cash provided by financing activities
13,390
Net increase in cash and cash equivalents
3,201
Cash and cash equivalents at beginning of period
5,028
Cash and cash equivalents at end of period
8,229
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

GRI Bio, Inc. (GRI)

GRI Bio, Inc. (GRI)